Cargando…

Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1

Isocitrate dehydrogenase (IDH) plays an indispensable role in the tricarboxylic acid cycle, and IDH mutations are present in nearly 75% of glioma and 20% of acute myeloid leukemia. One IDH1R132H inhibitor (clomifene citrate) was found by virtual screening method, which can selectively suppress mutan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Mengzhu, Sun, Weiguang, Gao, Suyu, Luan, Shanshan, Li, Dan, Chen, Renqi, Zhang, Qian, Chen, Lixia, Huang, Jiangeng, Li, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546478/ https://www.ncbi.nlm.nih.gov/pubmed/28498812 http://dx.doi.org/10.18632/oncotarget.17464

Ejemplares similares

A natural inhibitor of kidney-type glutaminase: a withanolide from Physalis pubescens with potent anti-tumor activity
por: Wu, Canrong, et al.
Publicado: (2017)

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
por: Popovici-Muller, Janeta, et al.
Publicado: (2018)

Proton pump inhibitor ilaprazole suppresses cancer growth by targeting T-cell-originated protein kinase
por: Zheng, Mengzhu, et al.
Publicado: (2017)

Highly fluorescent carbon dots as an efficient nanoprobe for detection of clomifene citrate
por: Zhang, Yi, et al.
Publicado: (2019)

Discovery of Potent c-MET Inhibitors with New Scaffold Having Different Quinazoline, Pyridine and Tetrahydro-Pyridothienopyrimidine Headgroups
por: Jiang, Yingnan, et al.
Publicado: (2016)

Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2
por: Li, Wei, et al.
Publicado: (2017)

Efficacy of clomifene citrate for the treatment of patients with polycystic ovary syndrome: A protocol of systematic review
por: Han, Qin-wei, et al.
Publicado: (2020)

Postoperative risk of IDH-mutant glioma–associated seizures and their potential management with IDH-mutant inhibitors
por: Drumm, Michael R., et al.
Publicado: (2023)

IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity
por: Khurshed, Mohammed, et al.
Publicado: (2018)

Discovery of novel IDH1-R132C inhibitors through structure-based virtual screening
por: Hu, Chujiao, et al.
Publicado: (2022)

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
por: DiNardo, Courtney D., et al.
Publicado: (2022)

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
por: Gupta, Charu, et al.
Publicado: (2020)

Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma
por: Fanucci, Kristina, et al.
Publicado: (2023)

Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas
por: Cho, Nicholas S, et al.
Publicado: (2022)

Recent advances of IDH1 mutant inhibitor in cancer therapy
por: Tian, Wangqi, et al.
Publicado: (2022)

Clomifene citrate or unstimulated intrauterine insemination compared with expectant management for unexplained infertility: pragmatic randomised controlled trial
por: Bhattacharya, S, et al.
Publicado: (2008)

Clomifene and Assisted Reproductive Technology in Humans Are Associated with Sex-Specific Offspring Epigenetic Alterations in Imprinted Control Regions
por: Lloyd, Dillon T., et al.
Publicado: (2022)

Therapies for IDH-Mutant Gliomas
por: Alshiekh Nasany, Ruham, et al.
Publicado: (2023)

Efficacy of clomifene citrate combined Bushen Culuan Decoction for the treatment of infertility caused by polycystic ovary syndrome: A protocol of systematic review
por: Feng, Jing, et al.
Publicado: (2020)

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo
por: Chaturvedi, A, et al.
Publicado: (2017)

Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
por: Unruh, Dusten, et al.
Publicado: (2019)

Mutant IDH1 is required for IDH1 mutated tumor cell growth
por: Jin, Genglin, et al.
Publicado: (2012)

Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia
por: Chaturvedi, Anuhar, et al.
Publicado: (2020)

Induction of sarcomas by mutant IDH2
por: Lu, Chao, et al.
Publicado: (2013)

Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?
por: Moll, E., et al.
Publicado: (2008)

IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat
por: Sears, Thomas K., et al.
Publicado: (2021)

In Vivo Anti-Tumor Effect of PARP Inhibition in IDH1/2 Mutant MDS/AML Resistant to Targeted Inhibitors of Mutant IDH1/2
por: Gbyli, Rana, et al.
Publicado: (2022)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Discovery of Quercetin and Its Analogs as Potent OXA-48 Beta-Lactamase Inhibitors
por: Zhang, Yuejuan, et al.
Publicado: (2022)

Discovery and characterization of potent And‐1 inhibitors for cancer treatment
por: Li, Jing, et al.
Publicado: (2021)

Stalled oligodendrocyte differentiation in IDH-mutant gliomas
por: Wei, Yanfei, et al.
Publicado: (2023)

Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma()()
por: Sun, Chao, et al.
Publicado: (2020)

Oligosarcomas, IDH-mutant are distinct and aggressive
por: Suwala, Abigail K., et al.
Publicado: (2021)

Deep Learning Can Differentiate IDH-Mutant from IDH-Wild GBM
por: Pasquini, Luca, et al.
Publicado: (2021)

The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma
por: Vo, Anh Huan, et al.
Publicado: (2022)

Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
por: Stuani, Lucille, et al.
Publicado: (2021)

Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors
por: Sule, Amrita, et al.
Publicado: (2021)

Retrospective examination of pseudoprogression in IDH mutant gliomas
por: Wetzel, Ethan A, et al.
Publicado: (2023)

The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas
por: Natsume, Atsushi, et al.
Publicado: (2022)

Discovery of Novel IDH1 Inhibitor Through Comparative Structure-Based Virtual Screening
por: Wang, Yuwei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_av8ek7qg7e5v0i59n5nn7vrqbm